Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,079 total articles

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Immatics N.V. presented updated Phase 1 clinical data at ASCO 2026 showing that their IMA203CD8 PRAME-directed TCR T-cell therapy achieved meaningful anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer, uterine cancer, and synovial sarcoma. The therapy demonstrated a 63% objective response rate in gynecologic c…

FCHL Receives Nasdaq Deficiency Notice on May 26, 2026

FCHL Receives Nasdaq Deficiency Notice on May 26, 2026

Fitness Champs Holdings Limited (NASDAQ: FCHL), a leading aquatic sports education provider in Singapore, received a Nasdaq deficiency notice due to reported stockholders' equity below the minimum requirement. Following a financing round in May 2026, the company believes it has regained compliance, pending Nasdaq's review. The company continues to …

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Inc., a regenerative and cellular medicine company, received a Nasdaq notification for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. Nasdaq granted the company a 60-day window to submit a compliance plan with a possible extension up to 180 days. Celularity is working to complete the filing …

Safe Bulkers, Inc. Announces Availability of 2025 Sustainability Report

Safe Bulkers, Inc. Announces Availability of 2025 Sustainability Report

Safe Bulkers, Inc., a NYSE-listed international marine drybulk transportation company, has published its 2025 Sustainability Report. The report, prepared following GRI Standards and SASB recommendations, outlines the company's environmental, social, and governance (ESG) initiatives and performance, reflecting its commitment to managing environmenta…

Notice of Settlement of Shareholder Derivative Actions

Notice of Settlement of Shareholder Derivative Actions

Olaplex Holdings, Inc. disclosed a proposed settlement of pending shareholder derivative lawsuits filed in the U.S. District Court for the Central District of California. The settlement includes adoption of corporate governance reforms and payment of legal fees, subject to court approval. This settlement aims to avoid prolonged litigation and assoc…

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

Jade Biosciences announced a conference call to discuss interim Phase 1 healthy volunteer results for JADE101, their novel anti-APRIL monoclonal antibody targeting immunoglobulin A nephropathy (IgAN). The data is expected to inform dosing strategy and characterize the clinical profile of this potentially best-in-class therapy. JADE101 shows promisi…

Arvinas to Present at Jefferies Global Healthcare Conference

Arvinas to Present at Jefferies Global Healthcare Conference

Arvinas, Inc., a clinical-stage biotech company specializing in targeted protein degradation therapies, announced its management will present at the Jefferies Global Healthcare Conference. The presentation will cover its PROTAC platform, FDA-approved drug VEPPANU™, and several investigational drugs targeting neurodegenerative diseases, cancers, and…

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa Pharmaceuticals International, plc announced management's participation in fireside chats at the Jefferies Global Healthcare Conference and Goldman Sachs Annual Global Healthcare Conference in June 2026. Presentations will be webcast live and available for replay on the company's website, highlighting the company's commitment to engaging wi…

Allied Gold Advances Receipt of Regulatory Approvals and Clearances in Connection with the Proposed Arrangement with Zijin Gold International and Extends the Outside Date to July 29, 2026

Allied Gold Advances Receipt of Regulatory Approvals and Clearances in Connection with the Proposed Arrangement with Zijin Gold International and Extends the Outside Date to July 29, 2026

Allied Gold Corporation announced significant progress in obtaining regulatory approvals from Canadian, West African, and other African authorities related to Zijin Gold's proposed acquisition of Allied Gold. The Investment Canada Act approval has been secured, marking a major milestone toward completing the transaction. The companies have extended…

Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing

Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing

Cuprina Holdings completed a reverse stock split to increase its share price and requested a hearing before the Nasdaq Hearings Panel to appeal a delisting decision after failing to meet Nasdaq's minimum bid price requirement. The company aims to maintain its listing on The Nasdaq Capital Market amid ongoing compliance challenges.

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MannKind Corporation announced FDA approval for Afrezza, the first inhaled mealtime insulin for children aged 6 and older with type 1 and type 2 diabetes. This approval provides a novel, needle-free insulin option that offers rapid onset and dosing flexibility, potentially improving glycemic control and quality of life for pediatric patients and th…

ATN International, Inc. to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 11, 2026 in New York

ATN International, Inc. to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 11, 2026 in New York

ATN International, a leading digital infrastructure and communications services provider, announced its participation in the 16th Annual East Coast IDEAS Investor Conference on June 11, 2026. The company will host one-on-one investor meetings and a live webcast presentation, highlighting its focus on rural and remote markets in the U.S. and Caribbe…